APO Research
Talk to an analyst

APO RESEARCH · REPORT

Severe Acute Respiratory Syndrome (SARS) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Analysis and Forecast 2026-2032

26 December 2025199 pages

Choose your research edition.

Industry ResearchSevere Acute Respiratory Syndrome (SARS) Therapeutics Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Severe Acute Respiratory Syndrome (SARS) Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Severe Acute Respiratory Syndrome (SARS) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Severe Acute Respiratory Syndrome (SARS) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Severe Acute Respiratory Syndrome (SARS) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Severe Acute Respiratory Syndrome (SARS) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Severe Acute Respiratory Syndrome (SARS) Therapeutics include CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC and Protein Sciences Corporation, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Severe Acute Respiratory Syndrome (SARS) Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Severe Acute Respiratory Syndrome (SARS) Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Severe Acute Respiratory Syndrome (SARS) Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Severe Acute Respiratory Syndrome (SARS) Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Severe Acute Respiratory Syndrome (SARS) Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Company

CEL-SCI Corporation

GeneCure LLC

Humabs BioMed SA

Inovio Pharmaceuticals, Inc.

Nanotherapeutics, Inc.

Novavax, Inc.

Phelix Therapeutics, LLC

Protein Sciences Corporation

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Type

LCA-60

INO-4500

FDX-000

D-3252

CEL-1000

Others

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Application

Research Center

Hospital

Clinic

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Severe Acute Respiratory Syndrome (SARS) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Severe Acute Respiratory Syndrome (SARS) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Severe Acute Respiratory Syndrome (SARS) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Severe Acute Respiratory Syndrome (SARS) Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Severe Acute Respiratory Syndrome (SARS) Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. LCA-60 Major Player Table 3. INO-4500 Major Player Table 4. FDX-000 Major Player Table 5. D-3252 Major Player Table 6. CEL-1000 Major Player Table 7. Others Major Player Table 8. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Research Center Major Player Table 10. Hospital Major Player Table 11. Clinic Major Player Table 12. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Trends Table 13. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Drivers Table 14. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Opportunities and Challenges Table 15. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Restraints Table 16. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region (2021-2026) Table 19. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region (2027-2032) Table 21. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Players (2021-2026) Table 23. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Key Players Headquarters & Area Served Table 25. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Players, Product Type & Application Table 26. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2021-2026) Table 33. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2027-2032) Table 34. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2021-2026) Table 38. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2027-2032) Table 39. CEL-SCI Corporation Company Information Table 40. CEL-SCI Corporation Business Overview Table 41. CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 43. CEL-SCI Corporation Recent Development Table 44. GeneCure LLC Company Information Table 45. GeneCure LLC Business Overview Table 46. GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 48. GeneCure LLC Recent Development Table 49. Humabs BioMed SA Company Information Table 50. Humabs BioMed SA Business Overview Table 51. Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 53. Humabs BioMed SA Recent Development Table 54. Inovio Pharmaceuticals, Inc. Company Information Table 55. Inovio Pharmaceuticals, Inc. Business Overview Table 56. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 58. Inovio Pharmaceuticals, Inc. Recent Development Table 59. Nanotherapeutics, Inc. Company Information Table 60. Nanotherapeutics, Inc. Business Overview Table 61. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 63. Nanotherapeutics, Inc. Recent Development Table 64. Novavax, Inc. Company Information Table 65. Novavax, Inc. Business Overview Table 66. Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 68. Novavax, Inc. Recent Development Table 69. Phelix Therapeutics, LLC Company Information Table 70. Phelix Therapeutics, LLC Business Overview Table 71. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 73. Phelix Therapeutics, LLC Recent Development Table 74. Protein Sciences Corporation Company Information Table 75. Protein Sciences Corporation Business Overview Table 76. Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 78. Protein Sciences Corporation Recent Development Table 79. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 80. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 81. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 82. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 83. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 84. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 85. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 86. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 87. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 88. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 89. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 90. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 92. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 93. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 94. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 95. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 96. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 97. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 98. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 99. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 100. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 101. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 103. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 104. SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 105. SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 106. SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 107. SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 108. SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 110. SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Severe Acute Respiratory Syndrome (SARS) Therapeutics Image Figure 2. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. LCA-60 Image Figure 5. INO-4500 Image Figure 6. FDX-000 Image Figure 7. D-3252 Image Figure 8. CEL-1000 Image Figure 9. Others Image Figure 10. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 12. Research Center Image Figure 13. Hospital Image Figure 14. Clinic Image Figure 15. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (US$ Million) & (2021-2032) Figure 16. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2021-2032) Figure 23. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2021-2032) Figure 26. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Type (2021-2032) Figure 28. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Application (2021-2032) Figure 29. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Country (2021-2032) Figure 30. United States Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Type (2021-2032) Figure 35. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Application (2021-2032) Figure 36. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Country (2021-2032) Figure 37. Germany Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Type (2021-2032) Figure 47. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Application (2021-2032) Figure 48. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Type (2021-2032) Figure 50. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Application (2021-2032) Figure 51. Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Region (2021-2032) Figure 52. Japan Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Type (2021-2032) Figure 60. SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Application (2021-2032) Figure 61. SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Country (2021-2032) Figure 62. Brazil Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • LCA-60
  • INO-4500
  • FDX-000
  • D-3252
  • CEL-1000
  • Others
Applications
  • Research Center
  • Hospital
  • Clinic
Companies covered
  • CEL-SCI Corporation
  • GeneCure LLC
  • Humabs BioMed SA
  • Inovio Pharmaceuticals, Inc.
  • Nanotherapeutics, Inc.
  • Novavax, Inc.
  • Phelix Therapeutics, LLC
  • Protein Sciences Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Type
  3. 1.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 LCA-60
  5. 1.2.3 INO-4500
  6. 1.2.4 FDX-000
  7. 1.2.5 D-3252
  8. 1.2.6 CEL-1000
  9. 1.2.7 Others
  10. 1.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Application
  11. 1.3.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Research Center
  13. 1.3.3 Hospital
  14. 1.3.4 Clinic
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Dynamics
  1. 2.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Trends
  2. 2.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Drivers
  3. 2.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Growth Trends by Region
  3. 3.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Players
  2. 4.1.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Players, Product Type & Application
  8. 4.5 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Severe Acute Respiratory Syndrome (SARS) Therapeutics Tier 1, Tier 2, and Tier 3
5 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type
  1. 5.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2021-2032)
6 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application
  1. 6.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 CEL-SCI Corporation
  2. 7.1.1 CEL-SCI Corporation Company Information
  3. 7.1.2 CEL-SCI Corporation Business Overview
  4. 7.1.3 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  6. 7.1.5 CEL-SCI Corporation Recent Developments
  7. 7.2 GeneCure LLC
  8. 7.2.1 GeneCure LLC Company Information
  9. 7.2.2 GeneCure LLC Business Overview
  10. 7.2.3 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  12. 7.2.5 GeneCure LLC Recent Developments
  13. 7.3 Humabs BioMed SA
  14. 7.3.1 Humabs BioMed SA Company Information
  15. 7.3.2 Humabs BioMed SA Business Overview
  16. 7.3.3 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  18. 7.3.5 Humabs BioMed SA Recent Developments
  19. 7.4 Inovio Pharmaceuticals, Inc.
  20. 7.4.1 Inovio Pharmaceuticals, Inc. Company Information
  21. 7.4.2 Inovio Pharmaceuticals, Inc. Business Overview
  22. 7.4.3 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  24. 7.4.5 Inovio Pharmaceuticals, Inc. Recent Developments
  25. 7.5 Nanotherapeutics, Inc.
  26. 7.5.1 Nanotherapeutics, Inc. Company Information
  27. 7.5.2 Nanotherapeutics, Inc. Business Overview
  28. 7.5.3 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  30. 7.5.5 Nanotherapeutics, Inc. Recent Developments
  31. 7.6 Novavax, Inc.
  32. 7.6.1 Novavax, Inc. Company Information
  33. 7.6.2 Novavax, Inc. Business Overview
  34. 7.6.3 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  36. 7.6.5 Novavax, Inc. Recent Developments
  37. 7.7 Phelix Therapeutics, LLC
  38. 7.7.1 Phelix Therapeutics, LLC Company Information
  39. 7.7.2 Phelix Therapeutics, LLC Business Overview
  40. 7.7.3 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  42. 7.7.5 Phelix Therapeutics, LLC Recent Developments
  43. 7.8 Protein Sciences Corporation
  44. 7.8.1 Protein Sciences Corporation Company Information
  45. 7.8.2 Protein Sciences Corporation Business Overview
  46. 7.8.3 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  48. 7.8.5 Protein Sciences Corporation Recent Developments
8 North America
  1. 8.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (2021-2032)
  2. 8.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country
  11. 8.6.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country
  11. 9.6.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (2021-2032)
  2. 10.2 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country
  11. 11.6.1 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst